智通财经APP获悉，长江生命科技(00775)绩后跌超6%，截至发稿，跌6.67%，报0.56港元，成交546.21万港元。
消息面上，3月18日，长江生命科技发布截至2024年12月31日止年度业绩，该集团期内取得收入55.23亿港元，同比增加3.76%；公司股东应占亏损1.27亿港元，去年同期则公司股东应占溢利1725万港元；每股基本亏损1.32港仙。
公告称，业绩于2023年至2024年期间由盈转亏，主要归因于两大因素：公司决意加速科研，投资于科研的支出由2023年1.46亿港元，上升至2024年2.54亿港元，按年增加1.08亿港元；以及葡萄园投资组合(除具出售协议之物业外)的公平值取得税后贬值，按年减少4040万港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.